Background
Glioblastoma multiforme (GBM) remains one of the most aggressive and lethal primary brain tumors, characterized by rapid progression and poor prognosis. Despite advances in surgery, radiotherapy, and chemotherapy, therapeutic options are limited and outcomes remain dismal. Identifying novel molecular targets is critical to developing more effective treatments. UniProt entry O94806 corresponds to a human protein whose role in GBM biology is currently uncharacterized. Preliminary expression profiling suggests altered regulation in GBM tissues, positioning O94806 as a putative target candidate warranting further investigation.
Data-mining rationale
To uncover novel candidates relevant to GBM, we cross-referenced reviewed human protein entries from UniProt annotated with "glioblastoma multiforme" against a comprehensive collection of 724 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). UniProt:O94806 emerged from this integrative screen as a gene exhibiting differential expression patterns in multiple GBM-related datasets (including GDS:200317497, GDS:200273558, GDS:200320501, GDS:200318047, and GDS:200318046). These datasets collectively profile gene expression in GBM versus normal brain tissues or across GBM subtypes, suggesting that O94806 may be involved in tumor biology. However, no registered clinical programs targeting O94806 were identified, highlighting a gap between molecular evidence and translational efforts.
Why prior analyses may have missed this
Many of the GEO datasets containing expression data for O94806 predate the widespread adoption of modern empirical-Bayes statistical methods such as limma, which improve sensitivity and specificity in detecting differentially expressed genes by properly accounting for multiple testing and variance estimation. Earlier analyses may have relied on less robust statistical approaches, potentially overlooking subtle but biologically meaningful expression changes of O94806. Additionally, limited sample sizes and heterogeneity in patient cohorts may have further obscured signals. A systematic re-analysis using updated bioinformatics pipelines with stringent false discovery rate control could clarify the significance of O94806 expression alterations in GBM.
Reasoning for further validation
Given the putative association of O94806 with GBM expression profiles and the lack of clinical development targeting this protein, several experimental steps are warranted to validate its candidacy:
- Re-analyze the matched GEO datasets using limma combined with Benjamini-Hochberg false discovery rate correction (FDR < 0.05) to robustly identify differential expression of O94806 and related genes.
- Validate top differentially expressed genes, including O94806, by quantitative PCR (qPCR) in independent GBM patient cohorts to confirm reproducibility.
- Assess tissue specificity and expression patterns of O94806 in normal and tumor tissues using resources such as GTEx and the Human Protein Atlas to understand its biological context and potential off-target risks.
- Employ protein-protein interaction and pathway analysis tools like STRING and OmniPath to elucidate the molecular networks involving O94806, which may reveal mechanistic insights or synergistic targets.
- If validation supports a role in GBM pathobiology, evaluate the druggability of O94806 through databases such as DGIdb and ChEMBL to identify existing compounds or guide novel therapeutic development.
This multi-tiered approach will help determine whether O94806 represents a viable molecular target for future translational research in glioblastoma multiforme.